The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00240643




Registration number
NCT00240643
Ethics application status
Date submitted
14/10/2005
Date registered
14/10/2005
Date last updated
13/01/2017

Titles & IDs
Public title
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
Scientific title
A Randomized, Double Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg and 500 mg) Administered Twice Daily for 16 Weeks, on Top of Asprin (325mg, qd) in Men and Women With Non Valvular Atrial Fibrillation at a Low or Intermediate Risk for Stroke
Secondary ID [1] 0 0
101724
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fibrillation, Atrial 0 0
Atrial Fibrillation 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SB424323

Treatment: Drugs: SB424323


Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Relationship between anti IIa (a biomarker)and the dose of SB424323.
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Blood levels of SB424323 during the study. Number of strokes, transient ischemic attacks or systemic embolism during the study. Changes in laboratory tests during the study.
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Patients with non valvular atrial fibrillation and any of the following:

- </= 60 years old with no heart disease.

- 60 years old with heart disease but no risk factors.

- >/=60 years old and </=75 years old with no risk factors and no heart disease.

- Must be able to take aspirin.
Minimum age
18 Years
Maximum age
75 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Previous heart attack or stroke.

- History of high blood pressure, diabetes or a prior blood clot.

- Liver or kidney disease.

- Need for anti-thrombotic or anti-platelet drugs.

- Need for cardiovascular medicines.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Michigan
Country [3] 0 0
United States of America
State/province [3] 0 0
Ohio
Country [4] 0 0
United States of America
State/province [4] 0 0
Pennsylvania
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas
Country [6] 0 0
United States of America
State/province [6] 0 0
Washington
Country [7] 0 0
United States of America
State/province [7] 0 0
Wisconsin
Country [8] 0 0
Argentina
State/province [8] 0 0
Buenos Aires
Country [9] 0 0
Argentina
State/province [9] 0 0
Córdova
Country [10] 0 0
Argentina
State/province [10] 0 0
Santa Fe
Country [11] 0 0
Argentina
State/province [11] 0 0
Ciudad Autónoma de Buenos Aires
Country [12] 0 0
Argentina
State/province [12] 0 0
Moron-Provincia de Buenos Aires
Country [13] 0 0
Belgium
State/province [13] 0 0
Antwerpen
Country [14] 0 0
Belgium
State/province [14] 0 0
Linkebeek
Country [15] 0 0
Brazil
State/province [15] 0 0
Rio Grande Do Sul
Country [16] 0 0
Brazil
State/province [16] 0 0
São Paulo
Country [17] 0 0
Canada
State/province [17] 0 0
Nova Scotia
Country [18] 0 0
Canada
State/province [18] 0 0
Ontario
Country [19] 0 0
Canada
State/province [19] 0 0
Quebec
Country [20] 0 0
Denmark
State/province [20] 0 0
Aarhus
Country [21] 0 0
Denmark
State/province [21] 0 0
Frederiksberg
Country [22] 0 0
Estonia
State/province [22] 0 0
Tallinn
Country [23] 0 0
Estonia
State/province [23] 0 0
Tartu
Country [24] 0 0
France
State/province [24] 0 0
Créteil
Country [25] 0 0
France
State/province [25] 0 0
Mont de Marsan
Country [26] 0 0
France
State/province [26] 0 0
Toulouse
Country [27] 0 0
France
State/province [27] 0 0
Tours
Country [28] 0 0
Germany
State/province [28] 0 0
Bayern
Country [29] 0 0
Germany
State/province [29] 0 0
Niedersachsen
Country [30] 0 0
Germany
State/province [30] 0 0
Sachsen-Anhalt
Country [31] 0 0
Germany
State/province [31] 0 0
Sachsen
Country [32] 0 0
Germany
State/province [32] 0 0
Schleswig-Holstein
Country [33] 0 0
Germany
State/province [33] 0 0
Thueringen
Country [34] 0 0
Germany
State/province [34] 0 0
Berlin
Country [35] 0 0
Greece
State/province [35] 0 0
Athens
Country [36] 0 0
Hungary
State/province [36] 0 0
Sopron
Country [37] 0 0
Hungary
State/province [37] 0 0
Szolnok
Country [38] 0 0
Hungary
State/province [38] 0 0
Székesfehérvár
Country [39] 0 0
India
State/province [39] 0 0
Bangalore
Country [40] 0 0
India
State/province [40] 0 0
Hyderabad
Country [41] 0 0
India
State/province [41] 0 0
Mumbai
Country [42] 0 0
India
State/province [42] 0 0
New Delhi
Country [43] 0 0
Italy
State/province [43] 0 0
Calabria
Country [44] 0 0
Italy
State/province [44] 0 0
Campania
Country [45] 0 0
Italy
State/province [45] 0 0
Lazio
Country [46] 0 0
Italy
State/province [46] 0 0
Umbria
Country [47] 0 0
Korea, Republic of
State/province [47] 0 0
Kwangju
Country [48] 0 0
Korea, Republic of
State/province [48] 0 0
Seoul
Country [49] 0 0
Latvia
State/province [49] 0 0
Riga
Country [50] 0 0
Mexico
State/province [50] 0 0
Mexico
Country [51] 0 0
Netherlands
State/province [51] 0 0
Delft
Country [52] 0 0
Netherlands
State/province [52] 0 0
Den Haag
Country [53] 0 0
Netherlands
State/province [53] 0 0
Utrecht
Country [54] 0 0
New Zealand
State/province [54] 0 0
Auckland
Country [55] 0 0
New Zealand
State/province [55] 0 0
Christchurch
Country [56] 0 0
New Zealand
State/province [56] 0 0
Hamilton
Country [57] 0 0
New Zealand
State/province [57] 0 0
Takapuna, Auckland
Country [58] 0 0
Norway
State/province [58] 0 0
Elverum
Country [59] 0 0
Norway
State/province [59] 0 0
Oslo
Country [60] 0 0
Norway
State/province [60] 0 0
Skien
Country [61] 0 0
Romania
State/province [61] 0 0
Bucharest
Country [62] 0 0
Romania
State/province [62] 0 0
Bucuresti
Country [63] 0 0
Romania
State/province [63] 0 0
Targu-Mures
Country [64] 0 0
Spain
State/province [64] 0 0
Alicante
Country [65] 0 0
Spain
State/province [65] 0 0
Barcelona
Country [66] 0 0
Spain
State/province [66] 0 0
Cadiz
Country [67] 0 0
Spain
State/province [67] 0 0
Leganes
Country [68] 0 0
Spain
State/province [68] 0 0
Madrid
Country [69] 0 0
Spain
State/province [69] 0 0
San Juan De Alicante
Country [70] 0 0
Sweden
State/province [70] 0 0
Göteborg
Country [71] 0 0
Sweden
State/province [71] 0 0
Stockholm
Country [72] 0 0
Sweden
State/province [72] 0 0
Uppsala
Country [73] 0 0
Taiwan
State/province [73] 0 0
Taipei
Country [74] 0 0
Thailand
State/province [74] 0 0
Bangkok
Country [75] 0 0
Thailand
State/province [75] 0 0
Chiangmai
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Lanarkshire
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Middlesex
Country [78] 0 0
United Kingdom
State/province [78] 0 0
West Midlands
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Antrim
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Dundee
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Manchester
Country [82] 0 0
United Kingdom
State/province [82] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323
in a relevant population. The data from this study will be used along with other data to aid
in choosing the most appropriate dose for the later phase study.
Trial website
https://clinicaltrials.gov/show/NCT00240643
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Other publications